Publications
Stay up to date with our literature reviews which are curated by experts to feature the most important publications released each month. Explore our publications for access to concise summary slides for your own use.
Efficacy and Safety of Canagliflozin Versus Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin (CANTATA-SU): 52 Week Results From a Randomised, Double-blind, Phase 3 Non-inferiority Trial
Lancet 2013;382:941–50 doi.org/10.1016/S0140-6736(13)60683-2
In the CANTATA-52 trial, canagliflozin was non-inferior to glimepiride for the primary endpoint of glucose-lowering at 52 weeks – and the highest dose achieved superiority.
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
N Engl J Med 2019;380:347–57 DOI 10.1056/NEJMoa1812389
Dapagliflozin was found to be noninferior to placebo in terms of major adverse cardiovascular events in the DECLARE-TIMI 58 trial.
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
N Engl J Med 2020;383:1413–24 DOI 10.1056/NEJMoa2022190
Empagliflozin demonstrated a reduction in CV death, HF hospitalisation, rate of eGFR decline and risk of serious renal outcomes in patients with chronic HF and reduced ejection fraction in the EMPEROR-reduced study.
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
N Engl J Med 2017;377:1228–39 DOI: 10.1056/NEJMoa1612917
The EXSCEL study showed that among patients with type 2 diabetes (T2D) with or without previous cardiovascular (CV) disease, the incidence of major adverse cardiovascular events (MACE) did not differ significantly between patients who received exenatide and those who received placebo.
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
N Engl J Med 2016;375:311–22 DOI: 10.1056/NEJMoa1603827
The LEADER trial demonstrated CV benefits with liraglutide, and showed that the rate of the first occurrence of death from cardiovascular (CV) causes, nonfatal myocardial infarction (MI), or nonfatal stroke among patients with type 2 diabetes (T2D) was lower with liraglutide than with placebo.